Retatrutide is getting a lot of attention. It’s a triple hormone receptor agonist, meaning it targets GIP, GLP-1, and glucagon receptors all at once. Early trial data shows weight loss results that go beyond what semaglutide or tirzepatide produce. People want access to it. That’s understandable.
But here’s the direct answer to the main question. Retatrutide is not approved in Australia. It is not available through standard prescription channels. As of 2025, it remains in Phase 3 clinical trials globally and has not received approval from the Therapeutic Goods Administration (TGA).
That doesn’t mean your options are zero. It means you need to understand the actual pathways that exist, what they require, and what approved alternatives are producing real results right now.
Is Retatrutide Approved for Use in Australia?
No. The TGA has not approved retatrutide. It is not listed on the Australian Register of Therapeutic Goods (ARTG). Eli Lilly, the manufacturer, is running Phase 3 trials but has not submitted for TGA approval yet.
Phase 2 trial data published in the New England Journal of Medicine in 2023 showed participants lost up to 24% of body weight over 48 weeks at the highest dose. That’s a significant number. For context, semaglutide (Ozempic/Wegovy) produces around 15% weight loss in trials, and tirzepatide (Mounjaro) around 20-22%. weight loss results
The mechanism is what makes retatrutide different. By hitting the glucagon receptor in addition to GIP and GLP-1, it increases energy expenditure, not just appetite suppression. In my reading of the trial data, that’s the part that stands out. Most GLP-1 drugs work primarily by reducing how much you eat. Retatrutide also appears to increase how much energy your body burns at rest.
But approved and available are two different things. Right now in Australia, it is neither.
Can I Access Retatrutide Through the TGA Special Access Scheme?
This is the question most people land on after they find out retatrutide isn’t approved. The TGA Special Access Scheme (SAS) does allow doctors to apply for access to unapproved medicines in specific circumstances.
There are two main categories under the SAS. Category A covers patients who are seriously ill with a condition that is life-threatening or has the potential to cause serious long-term morbidity. Category B requires a doctor to submit an application to the TGA and receive approval before prescribing.
For retatrutide specifically, SAS access is extremely unlikely at this stage. The TGA evaluates SAS applications based on available safety and efficacy data. Because retatrutide is still in Phase 3 trials, the full safety profile is not yet established. The TGA is unlikely to approve SAS applications for a drug that hasn’t completed its trial program.
I’ve seen people online claim they accessed retatrutide through compounding pharmacies or overseas suppliers. That pathway carries serious legal and health risks. Compounding a drug that has no approved formulation in Australia sits in a grey area at best and an illegal one at worst. The quality, dosing accuracy, and sterility of compounded versions of unapproved drugs are not regulated.
The honest answer is that SAS is a theoretical pathway, not a practical one for retatrutide right now.
Are There Clinical Trials for Retatrutide Available in Australia?
This is worth checking. Clinical trials are the one legitimate way to access retatrutide before approval.
Eli Lilly’s TRIUMPH trial program for retatrutide includes multiple Phase 3 studies. Some of these trials have sites in Australia. The Australian New Zealand Clinical Trials Registry (ANZCTR) and the ClinicalTrials.gov database are the two places to search for active trials recruiting participants in Australia.
To find out if you qualify, you’d search for retatrutide on ClinicalTrials.gov and filter by country. Trial eligibility criteria typically include BMI thresholds, age ranges, and exclusion criteria around existing medical conditions or medications.
Participating in a trial means you may receive the drug, or you may receive a placebo. You won’t know which. But it’s the only way to access retatrutide legally and with medical supervision in Australia right now.
If trials are your route, talk to your doctor first. They can help you assess eligibility and refer you to the relevant research teams.
What Doctors in Australia Can Prescribe Weight Loss Medications?
For approved weight loss medications, GPs can prescribe them. For more complex cases, endocrinologists and bariatric physicians are the specialists who manage obesity medicine.
The key point here is that the conversation with your doctor matters. Many GPs are not proactive about raising weight management medications. You often need to bring it up directly and come prepared with information about your health history, BMI, and what you’ve already tried.
When I look at how people successfully navigate this, the ones who get results are the ones who frame the conversation around health markers, not just weight. Blood pressure, blood glucose, HbA1c, lipid panels. These give your doctor clinical reasons to act, not just aesthetic ones.
Telehealth platforms have also made access easier. Services that connect patients with doctors experienced in metabolic health and weight management medications have grown significantly in Australia since 2022. These doctors are often more familiar with the current evidence base than a general GP who sees weight management as a small part of their practice.
How Do I Talk to My Doctor About Getting Access to Retatrutide in Australia?
Be direct. Tell your doctor you’ve been researching retatrutide, you understand it’s not approved in Australia, and you want to understand your options. Ask specifically about the TGA Special Access Scheme, clinical trial eligibility, and what approved alternatives they’d recommend given your health profile.
Doctors respond better to informed patients who ask specific questions than to patients who just say they want a specific drug. Show that you understand the regulatory situation. That changes the dynamic of the conversation.
Bring your numbers. BMI, waist circumference, any metabolic bloodwork you have. If you have a BMI over 30, or over 27 with a weight-related health condition, you meet the clinical threshold that most approved weight loss medications require in Australia.
If your GP isn’t familiar with the current options, ask for a referral to an endocrinologist or a doctor who specialises in obesity medicine. This is a reasonable request and a good GP will support it.
What Are the Approved Alternatives to Retatrutide for Weight Management in Australia?
This is where the practical conversation starts. There are real, approved options available now that produce significant results.
Semaglutide (Ozempic and Wegovy)
Semaglutide is a GLP-1 receptor agonist. Ozempic is approved for type 2 diabetes management and is widely prescribed off-label for weight loss. Wegovy, the higher-dose version specifically approved for weight management, received TGA approval in Australia in 2023.
Trial data from the STEP program shows an average of 14.9% body weight reduction over 68 weeks. In my reading of the real-world data, people who combine semaglutide with structured nutrition and resistance training see better outcomes than those who rely on the medication alone.
Tirzepatide (Mounjaro)
Tirzepatide targets both GLP-1 and GIP receptors. The SURMOUNT trial showed average weight loss of 20.9% at the highest dose over 72 weeks. Mounjaro received TGA approval in Australia for type 2 diabetes in 2023, and the weight management indication is progressing through the approval process.
This is the closest approved option to retatrutide in terms of mechanism and results. If you’re asking how to get prescribed retatrutide in Australia and the answer is that you can’t yet, tirzepatide is the most relevant alternative to discuss with your doctor.
Liraglutide (Saxenda)
Liraglutide was the first GLP-1 drug approved specifically for weight management in Australia. It requires daily injections compared to weekly for semaglutide and tirzepatide. Results are more modest, around 8% average weight loss. It’s still a valid option, particularly for people who don’t tolerate semaglutide well.
Orlistat (Xenical)
Orlistat works differently. It blocks fat absorption in the gut rather than acting on appetite hormones. It’s available over the counter in lower doses. Results are modest and the gastrointestinal side effects are significant for many people. Most people who are researching retatrutide are past this option, but it exists.
What Does the Evidence Actually Say About Triple Agonists Like Retatrutide?
The Phase 2 data for retatrutide published in the New England Journal of Medicine showed dose-dependent weight loss ranging from 8.7% to 24.2% over 48 weeks. The highest dose group saw results that no approved drug currently matches.
What I find interesting in the data is the metabolic profile. Participants showed improvements in fasting glucose, insulin resistance, blood pressure, and lipid levels alongside the weight loss. This suggests the drug is doing more than just reducing calorie intake.
The glucagon receptor component is the novel part. Glucagon normally raises blood glucose and increases energy expenditure. By activating it alongside GLP-1 and GIP, retatrutide appears to drive a higher metabolic rate. The concern with glucagon activation has historically been blood glucose elevation, but the GLP-1 component appears to offset that in the trial data.
Phase 3 results will tell us more about long-term safety, cardiovascular outcomes, and how the drug performs in broader populations. Until that data is published and reviewed by the TGA, the approval timeline in Australia remains uncertain.
FAQ
Is retatrutide legal in Australia?
It is not approved, which means it cannot be legally prescribed through standard channels. Importing it personally or accessing it through unregulated sources carries legal and health risks.
When will retatrutide be approved in Australia?
No confirmed timeline exists. Phase 3 trials are ongoing. After trial completion, Eli Lilly would need to submit a TGA application, which then goes through a review process that typically takes 12 to 18 months. A realistic estimate for potential TGA approval would be 2026 at the earliest, and that’s optimistic.
Can I get retatrutide from an overseas pharmacy?
Importing prescription medicines into Australia for personal use is regulated under the TGA’s Personal Importation Scheme. This allows individuals to import a three-month supply of a medicine they have a valid prescription for. Retatrutide has no approved prescription anywhere in the world yet, so this pathway doesn’t apply.
Is tirzepatide the same as retatrutide?
No. Tirzepatide targets two receptors, GLP-1 and GIP. Retatrutide targets three, adding the glucagon receptor. They are different drugs with different mechanisms, though both are made by Eli Lilly and both produce significant weight loss.
Do I need a specialist to get weight loss medication in Australia?
No. A GP can prescribe approved weight loss medications. A specialist referral helps if your GP is unfamiliar with the current options or if you have complex metabolic health needs.
The Practical Path Forward
If you’re serious about weight management right now, the path is clear. Talk to a doctor who understands metabolic health and the current medication options. Get your health markers assessed. Explore whether tirzepatide or semaglutide is appropriate for your situation. Check ClinicalTrials.gov for active retatrutide trials in Australia if you want to pursue that route.
Pair whatever medical approach you take with structured resistance training and a protein-focused nutrition plan. The trial data on GLP-1 and dual agonist drugs consistently shows better outcomes when exercise is part of the program. Muscle preservation during significant weight loss requires deliberate effort, and that’s where working with an experienced online personal trainer makes a real difference to your long-term results.
Retatrutide will likely be available in Australia eventually. Right now, the approved options are producing results that weren’t possible five years ago, and the infrastructure to support you through that process exists today.
